Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,103,055 shares of the biotechnology company's stock after buying an additional 114,167 shares during the quarter. Ascendis Pharma A/S accounts for 9.9% of Avoro Capital Advisors LLC's holdings, making the stock its 3rd largest holding. Avoro Capital Advisors LLC owned approximately 8.41% of Ascendis Pharma A/S worth $702,538,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ASND. Stifel Financial Corp increased its position in shares of Ascendis Pharma A/S by 36.1% during the fourth quarter. Stifel Financial Corp now owns 17,097 shares of the biotechnology company's stock worth $2,354,000 after acquiring an additional 4,534 shares during the period. Tower Research Capital LLC TRC grew its stake in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares in the last quarter. Capital International Inc. CA purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth about $1,153,000. Capital International Ltd. CA acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at about $2,637,000. Finally, Capital Group Investment Management PTE. LTD. purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $497,000.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded up $3.70 during mid-day trading on Friday, reaching $164.15. The stock had a trading volume of 560,181 shares, compared to its average volume of 488,001. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37. The business has a 50 day simple moving average of $153.64 and a 200 day simple moving average of $138.68. The firm has a market capitalization of $10.01 billion, a price-to-earnings ratio of -23.12 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

ASND has been the topic of a number of recent research reports. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. Cantor Fitzgerald increased their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. Finally, Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and a consensus price target of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.